About
CEVR Team
Careers
Read for the Registry
Contact Us
News & Events
News
Events
Publications
Projects
Databases
CEA Registry
GH CEA Registry
SPEC Database
Sponsorship
Sponsor login
Contact Us
News & Events
News
New Study Sheds Light on QALY and Disability Debate
A new study published in Value in Health, co-authored by CEVR’s Peter Neumann, shows no evidence that the use of quality-adjusted life years (QALYs) d...
CEVR Welcomes 2026 CEA Registry Summer Fellows
CEVR Welcomes 2026 CEA Registry Summer Fellows CEVR is thrilled to introduce the 2026 cohort of the Tufts-CEVR CEA Registry Summer Fellowship program,...
The Tufts-CEVR HEOR Leaders Survey: How worried should HEOR be about its future?
How worried should HEOR be about its future? A survey of US pharma HEOR leaders Peter J. Neumann, ScD,a Grace Hatfield, BA,a Tom Hughes, BScPharm,b ...
View All News Items
Events
CEVR Health Policy Seminar with Olivier Wouters PhD
CEVR’s Peter Neumann to Join Kaiser Permanente Fireside Chat: “Tough Pill to Swallow: Balancing Access and Affordability in Pharmacy”
Peter Neumann to Speak at ISPOR Boston Chapter Meeting on FDA Communications, Evidence Dissemination & RWE
View All Events
Publications
ISPOR 2026 (Poster Presentation)
Comparative Analysis of Oncology Therapy Approvals in the U.S. and Most Favored Nation Countries
PharmacoEconomics
Value of Knowing the Risk of Developing a Neurodegenerative Disease: A Discrete Choice Experiment
JAMA Dermatology
Variation in Coverage of Atopic Dermatitis Therapies Across Commercial Payers
Journal of Managed Care & Specialty Pharmacy
US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness
Health Affairs Forefront
Lessons From TAVR For Medicare’s ‘Coverage With Evidence Development’ Program
Learning Health Systems
Effect of Using Personalized Estimates of Diabetes Risk During Primary Care Visits for People With Prediabetes
JCO Oncology Practice
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024
ISPOR 2026 (Poster Presentation)
Variation in Commercial Health Plan Coverage of Atopic Dermatitis Therapies
ISPOR 2026 (Poster Presentation)
Alignment of Health Plan Reauthorization Criteria with Clinical Trial Endpoints for Neuromuscular Disease Therapies
View All Publications
